Role of 18FDG PET/CT in Detecting Primary Tumors in Patients with Carcinoma of Unknown Primary: Single-Center Cross-Sectional Study from 2017 to 2023 (Extension Study)

<b>Background</b> Carcinoma of unknown primary (CUP) is a diverse group of cancers in which the primary tumor site remains occult despite detailed investigations. This is an extension of a published parent study with a smaller cohort, to further validate the published facts of detection efficiency of 18F-fluorodeoxyglucose positron emission tomography/computed tomography ( <sup>18</sup> FDG PET/CT) in patients with CUP over a larger sample from 2017 to 2023. <b>Methods</b> Patients with CUP referred for <sup>18</sup> FDG PET/CT scan for detection of primary sites during the study period were recruited. <sup>18</sup> FDG PET/CT scan was acquired using a standardized protocol, and patients with suspected primary sites underwent biopsies. Scan findings and biopsy results were analyzed to find the detection rate, sensitivity, area under the curve (AUC), and positive predictive value (PPV). As no biopsy was performed in cases with negative scan, these cases were considered false negatives (FNs). <b>Results</b> Total 230 patients with CUP were included with similar demographic trend (mean age: 58 ± 14 years; 63% male and 37% female; mean body mass index: 26.82 ± 5.4 kg/m <sup>2</sup> ); 138/230 (60 vs. 74% in parent study) patients were found to have a hypermetabolic focus suggestive of primary tumor sites and subjected to biopsy which turned out positive in 127/138 (true positive [TP]: 92 vs. 76% in parent study) and negative in 11/138 (true negative [TN]: 8 vs. 24% in parent study). Sensitivity and PPV of <sup>18</sup> FDG PET/CT were 58 and 92%, respectively (68 and 76%, respectively, in parent study). The remaining 92/230 (40%) patients with negative <sup>18</sup> FDG PET/CT for primary focus did not have biopsy. No significant demographic difference was seen in patients with TP and FN studies ( <i>p</i> > 0.05). Receiver operating characteristics (ROC) curve revealed fair diagnostic strength of <sup>18</sup> FDG PET/CT for detecting unknown primary (AUC 0.710; <i>p</i> ≤ 0.05; standard error = 0.0167; confidence interval: 0.647-0.768; vs. nonsignificant in parent study). <b>Conclusion</b> We conclude that this extension study with a larger cohort compared with the parent study has found a similar detection efficiency of <sup>18</sup> FDG PET/CT for identifying primary tumor in patients with CUP (58 vs. 57%) but with better PPV and sensitivity. Upfront use of <sup>18</sup> FDG PET/CT in CUP could preclude the use of many futile diagnostic procedures. Furthermore, the use of tumor-specific PET tracers, higher resolution scanners, and acquiring delayed images in patients with negative <sup>18</sup> FDG study could reduce FN results in patients with CUP.

Authors

Institutions

Publication Details

Journal
World Journal of Nuclear Medicine
Published
2024-11-19
DOI
https://doi.org/10.1055/s-0044-1795101
Primary Topic
Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Role of 18FDG PET/CT in Detecting Primary Tumors in Patients with Carcinoma of Unknown Primary: Single-Center Cross-Sectional Study from 2017 to 2023 (Extension Study)

Shadi Azam, Nosheen Fatima, Maseeh uz Zaman, Mina Laiq et al.
World Journal of Nuclear Medicine
Cancer Diagnosis and Treatment
article

Role of 18FDG PET/CT in Detecting Primary Tumors in Patients with Carcinoma of Unknown Primary: Single-Center Cross-Sectional Study from 2017 to 2023 (Extension Study)

Shadi Azam, Nosheen Fatima, Maseeh uz Zaman, Mina Laiq, Muhammad Rafay
article en

Abstract

<b>Background</b> Carcinoma of unknown primary (CUP) is a diverse group of cancers in which the primary tumor site remains occult despite detailed investigations. This is an extension of a published parent study with a smaller cohort, to further validate the published facts of detection efficiency of 18F-fluorodeoxyglucose positron emission tomography/computed tomography ( <sup>18</sup> FDG PET/CT) in patients with CUP over a larger sample from 2017 to 2023. <b>Methods</b> Patients with CUP referred for <sup>18</sup> FDG PET/CT scan for detection of primary sites during the study period were recruited. <sup>18</sup> FDG PET/CT scan was acquired using a standardized protocol, and patients with suspected primary sites underwent biopsies. Scan findings and biopsy results were analyzed to find the detection rate, sensitivity, area under the curve (AUC), and positive predictive value (PPV). As no biopsy was performed in cases with negative scan, these cases were considered false negatives (FNs). <b>Results</b> Total 230 patients with CUP were included with similar demographic trend (mean age: 58 ± 14 years; 63% male and 37% female; mean body mass index: 26.82 ± 5.4 kg/m <sup>2</sup> ); 138/230 (60 vs. 74% in parent study) patients were found to have a hypermetabolic focus suggestive of primary tumor sites and subjected to biopsy which turned out positive in 127/138 (true positive [TP]: 92 vs. 76% in parent study) and negative in 11/138 (true negative [TN]: 8 vs. 24% in parent study). Sensitivity and PPV of <sup>18</sup> FDG PET/CT were 58 and 92%, respectively (68 and 76%, respectively, in parent study). The remaining 92/230 (40%) patients with negative <sup>18</sup> FDG PET/CT for primary focus did not have biopsy. No significant demographic difference was seen in patients with TP and FN studies ( <i>p</i> > 0.05). Receiver operating characteristics (ROC) curve revealed fair diagnostic strength of <sup>18</sup> FDG PET/CT for detecting unknown primary (AUC 0.710; <i>p</i> ≤ 0.05; standard error = 0.0167; confidence interval: 0.647-0.768; vs. nonsignificant in parent study). <b>Conclusion</b> We conclude that this extension study with a larger cohort compared with the parent study has found a similar detection efficiency of <sup>18</sup> FDG PET/CT for identifying primary tumor in patients with CUP (58 vs. 57%) but with better PPV and sensitivity. Upfront use of <sup>18</sup> FDG PET/CT in CUP could preclude the use of many futile diagnostic procedures. Furthermore, the use of tumor-specific PET tracers, higher resolution scanners, and acquiring delayed images in patients with negative <sup>18</sup> FDG study could reduce FN results in patients with CUP.

World Journal of Nuclear MedicineVol. 24(01)
Aga Khan University Hospital (PK)
Good health and well-being
Openalex Percentile: Top 63%
Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.